Visualization of product performance in the gut: what role in the drug development/regulatory paradigm?
Wilding
I R
IR
Pharmaceutical Profiles Limited, Nottingham, United Kingdom.
Heald
D L
DL
D000328:Adult; D000959:Antihypertensive Agents / Q000493:pharmacokinetics*; D018592:Cross-Over Studies; D003692:Delayed-Action Preparations / Q000493:pharmacokinetics*; D004041:Dietary Fats; D004064:Digestive System / Q000000981:diagnostic imaging* / Q000378:metabolism*; D004110:Diltiazem / Q000493:pharmacokinetics*; D005069:Evaluation Studies as Topic; D005215:Fasting; D006801:Humans; D009501:Neutron Activation Analysis; D011868:Radioisotopes; D011877:Radionuclide Imaging; D012493:Samarium; D013607:Tablets
D000959:Antihypertensive Agents; D003692:Delayed-Action Preparations; D004041:Dietary Fats; D011868:Radioisotopes; D013607:Tablets; D012493:Samarium; D004110:Diltiazem